Hiper-homocisteinemia e síndrome antifosfolípide primária

Carvalho, Jozélio Freire de; Caleiro, Maria Teresa Correia; Bonfá, Eloísa

doi:10.1590/s0482-50042009000400002

Cited by 3 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it is also necessary to highlight the role of nontraditional risk factors in this process, such as hyperhomocysteinemia and lipoprotein a [40]. …”

Section: Nontraditional Risk Factormentioning

confidence: 99%

“…However, when comparing this sample with individuals who had normal levels of homocysteine, there were no significant clinical and laboratory changes [40]. …”

Section: Nontraditional Risk Factormentioning

confidence: 99%

“…The influence of traditional cardiovascular risk factors in the development of thromboembolic events in patients with APS is relatively well explored in the literature. However, it is also necessary to highlight the role of nontraditional risk factors in this process, such as hyperhomocysteinemia and lipoprotein a [ 40 ].…”

Section: Nontraditional Risk Factormentioning

confidence: 99%

“…A recent cross-sectional study involving 27 patients with primary APS found a percentage of 22% of hyperhomocysteinemia. However, when comparing this sample with individuals who had normal levels of homocysteine, there were no significant clinical and laboratory changes [ 40 ].…”

Section: Nontraditional Risk Factormentioning

confidence: 99%

See 3 more Smart Citations

Cardiovascular Risk Factors in the Antiphospholipid Syndrome

Silva

Levy

Carvalho

2014

Journal of Immunology Research

View full text Add to dashboard Cite

A major cause of morbidity and mortality in the context of the antiphospholipid syndrome (APS) is the occurrence of thrombotic events. Besides the pathogenic roles of antiphospholipid antibodies (aPL), other risk factors and medical conditions, which are conditions for traditional risk of an individual without the APS, can coexist in this patient, raising their risk of developing thrombosis. Therefore, the clinical and laboratory investigation of comorbidities known to increase cardiovascular risk in patients with antiphospholipid antibody syndrome is crucial for the adoption of a more complete and effective treatment. Experimental models and clinical studies show evidence of association between APS and premature formation of atherosclerotic plaques. Atherosclerosis has major traditional risk factors: hypertension, diabetes mellitus, obesity, dyslipidemia, smoking, and sedentary lifestyle that may be implicated in vascular involvement in patients with APS. The influence of nontraditional risk factors as hyperhomocysteinemia, increased lipoprotein a, and anti-oxLDL in the development of thromboembolic events in APS patients has been studied in scientific literature. Metabolic syndrome with all its components also has been recently studied in antiphospholipid syndrome and is associated with arterial events.

show abstract

“…However, it is also necessary to highlight the role of nontraditional risk factors in this process, such as hyperhomocysteinemia and lipoprotein a [40]. …”

Section: Nontraditional Risk Factormentioning

confidence: 99%

“…However, when comparing this sample with individuals who had normal levels of homocysteine, there were no significant clinical and laboratory changes [40]. …”

Section: Nontraditional Risk Factormentioning

confidence: 99%

Section: Nontraditional Risk Factormentioning

confidence: 99%

Section: Nontraditional Risk Factormentioning

confidence: 99%

See 2 more Smart Citations

Cardiovascular Risk Factors in the Antiphospholipid Syndrome

Silva

Levy

Carvalho

2014

Journal of Immunology Research

View full text Add to dashboard Cite

show abstract

“…Hyperhomocysteinemia is known to coexist in patients with primary APS, with a reported rate of 30.8% [ 5 ], with smaller studies reporting high levels of homocysteine in 22% to 34.4% in patients with primary APS [ 7 , 8 ]. Additionally, high homocysteine levels can be related to the positivity of multiple antiphospholipid antibodies and simultaneous vascular events [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

A 25-Year-Old Woman with a High-Risk Large and Occlusive Pulmonary Embolism, Later Diagnosed with Primary Antiphospholipid Syndrome and Hyperhomocysteinemia: A Case Report

et al. 2023

View full text Add to dashboard Cite

Challenging differential diagnosis Background:High-risk pulmonary embolism (PE) occurs when the pulmonary circulation is suddenly occluded by a thrombus and is a life-threatening medical emergency. In young and otherwise healthy individuals, there may be undiagnosed underlying risk factors for PE that require investigation. This report presents the case of a 25-yearold woman admitted as an emergency with a high-risk large and occlusive PE, later diagnosed with primary antiphospholipid syndrome (APS) and hyperhomocysteinemia. Case Report:A 25-year-old woman presented with sudden-onset dyspnea after elective cholecystectomy. One year earlier, the patient had lower limb deep vein thrombosis without an identified predisposing cause, and she received anticoagulation for 6 months. On physical examination, she had right leg edema. Laboratory tests revealed elevated levels of troponin, pro-B-type natriuretic peptide, and D-dimer. Computed tomography pulmonary angiography (CTPA) demonstrated a large and occlusive PE, and an echocardiogram showed right ventricular dysfunction. Successful thrombolysis was performed with alteplase. On repeat CTPA, a significant reduction in filling defects in the pulmonary vasculature was observed. The patient evolved uneventfully and was discharged home on a vitamin K antagonist. Due to unprovoked recurrent thrombotic events, suspicion of underlying thrombophilia was raised, and hypercoagulability studies confirmed primary APS and hyperhomocysteinemia. Conclusions:This report presents the case of a life-threatening high-risk PE in a previously healthy young woman and highlights the importance of emergency management followed by investigation and treatment of underlying risk factors for venous thromboembolism, including APS and hyperhomocysteinemia.

show abstract

Antiphospholipid antibodies as biomarkers in psychiatry: review of psychiatric manifestations in antiphospholipid syndrome

Rege

Mackworth‐Young

2015

Translational Developmental Psychiatry

View full text Add to dashboard Cite

Antiphospholipid syndrome (APS) has been implicated in a range of neuropsychiatric presentations. However, there is a paucity of systematic studies on APS in psychiatry. This paper reports the clinical manifestations of APS that are relevant to psychiatrists. The aspects of APS pathogenesis, diagnosis, and treatment presented in this paper are based on a literature review. Treatment-resistant and atypical psychiatric illnesses, severe cognitive dysfunction, migraines, transient ischaemic attacks, and thromboembolic episodes, along with characteristic skin manifestations are the common clinical features of this syndrome. Antiphospholipid antibodies (aPL) may have a causal role in the development of some neuropsychiatric conditions. The existing criteria of APS may not apply to psychiatric patients, which may result in the underdiagnosis of APS in psychiatry. There is no evidence-based guidance available for the treatment of APS in patients with psychiatric symptoms. The treatment of APS with antithrombotic agents in case reports has been reported to yield dramatic improvements in complex and treatment-resistant cases. The possibility of a causal role of aPL in high-morbidity conditions, such as psychosis, depression, and dementia, requires the psychiatrist to be vigilant to the occurrence of this syndrome. There is an urgent need to conduct studies that elucidate the role of aPL in psychiatric presentations, identify patient characteristics, and consider whether new criteria with greater applicability in psychiatry are needed.

show abstract

Hiper-homocisteinemia e síndrome antifosfolípide primária

Cited by 3 publications

References 17 publications

Cardiovascular Risk Factors in the Antiphospholipid Syndrome

Cardiovascular Risk Factors in the Antiphospholipid Syndrome

A 25-Year-Old Woman with a High-Risk Large and Occlusive Pulmonary Embolism, Later Diagnosed with Primary Antiphospholipid Syndrome and Hyperhomocysteinemia: A Case Report

Antiphospholipid antibodies as biomarkers in psychiatry: review of psychiatric manifestations in antiphospholipid syndrome

Contact Info

Product

Resources

About